Press Release
<< Back
Verastem to Present at the 2013 ASCO Annual Meeting
The design of the ongoing Phase 1/1b trial of lead Focal Adhesion Kinase
(FAK) inhibitor VS-6063 in combination with paclitaxel in patients with
ovarian cancer will be presented. The study is currently enrolling
patients at three sites in the US. Howard “Skip” Burris, III, M.D.,
Chief Medical Officer,
“The women that are undergoing treatment have received multiple lines of prior chemotherapy,” said Dr. Burris. “There is a growing body of evidence that chemotherapeutics, including platinum- and taxane-based therapies, preferentially select for chemo-resistant cancer stem cells. By combining paclitaxel with the cancer stem cell-targeting FAK inhibitor VS-6063 we hope to address this challenge in the management of ovarian tumors.”
In addition to the ongoing Phase 1/1b trial to be presented,
The schedule for the
Date & Time:
Poster
Title: A phase I/IB study of paclitaxel in combination with VS-6063,
a focal adhesion kinase (FAK) inhibitor, in patients (pts) with advanced
ovarian cancer
Abstract Number: TPS2620
Session ID: General
Poster Session: Developmental Therapeutics, Clinical Pharmacology and
Experimental Therapeutics – Cancer Stem Cell Pathway
Location:
S Hall A2
Date & Time:
Poster
Title: Exploration of a plucked hair gene signature as a potential
pharmacodynamic marker for the dual PI3K/mTOR inhibitor VS-5584
Abstract
Number: 11064
Session ID: General Poster Session: Tumor
Biology Track
Location: S Hall A2
About
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development of the Company’s compounds, including VS-6063,
VS-4718 and VS-5584, and the Company’s FAK, PI3K/mTOR and diagnostic
programs generally, the timeline for clinical development and regulatory
approval of the Company’s compounds and the structure of the Company’s
planned clinical trials. The words “anticipate,” “appear,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,”
“target,” “potential,” “will,” “would,” “could,” “should,” “continue,”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. Each forward-looking statement is subject to risks
and uncertainties that could cause actual results to differ materially
from those expressed or implied in such statement. Applicable risks and
uncertainties include the risks that the preclinical testing of the
Company’s compounds may not be predictive of the success of later
clinical trials, that the Company will be unable to successfully
complete the clinical development of its compounds, including VS-6063,
VS-4718 and VS-5584, that the development of the Company’s compounds
will take longer or cost more than planned, and that the Company’s
compounds will not receive regulatory approval or become commercially
successful products. Other risks and uncertainties include those
identified under the heading “Risk Factors” in the Company’s Annual
Report on Form 10-K for the year ended
Source:
Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com